Pharmacokinetic-Pharmacodynamic Modeling of Buspirone and Its Metabolite 1-(2-Pyrimidinyl)-piperazine in Rats

@article{Zuideveld2002PharmacokineticPharmacodynamicMO,
  title={Pharmacokinetic-Pharmacodynamic Modeling of Buspirone and Its Metabolite 1-(2-Pyrimidinyl)-piperazine in Rats},
  author={Klaas P. Zuideveld and Jasna Rusi{\'c}-Pavleti{\'c} and Hugo J. Maas and L. A. Peletier and Piet H. van der Graaf and Meindert Danhof},
  journal={Journal of Pharmacology and Experimental Therapeutics},
  year={2002},
  volume={303},
  pages={1130 - 1137}
}
The objective of this investigation was to compare the in vivo potency and intrinsic activity of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine (1-PP) in rats by pharmacokinetic-pharmacodynamic modeling. Following intravenous administration of buspirone (5 or 15 mg/kg in 15 min) or 1-PP (10 mg/kg in 15 min), the time course of the concentrations in blood were determined in conjunction with the effect on body temperature. The pharmacokinetics of buspirone and 1-PP were analyzed based… Expand
6-Hydroxybuspirone Is a Major Active Metabolite of Buspirone: Assessment of Pharmacokinetics and 5-Hydroxytryptamine1A Receptor Occupancy in Rats
TLDR
Preclinical data suggest that 6-OH-buspirone probably contributes to the clinical efficacy of buspirone as an anxiolytic agent. Expand
Pharmacokinetic–Pharmacodynamic Modeling of the Hydroxy Lerisetron Metabolite L6-OH in Rats: An Integrated Parent–Metabolite Model
TLDR
It is concluded that after lerisetron administration, L6-OH is extensively formed in the rat but it is quickly eliminated; therefore, besides being equipotent with the parent drug, the L 6-OH metabolite does not influence the effect of ler isetron. Expand
Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling of 5-HT1A Receptor Agonists: Estimation of in Vivo Affinity and Intrinsic Efficacy on Body Temperature in Rats
TLDR
A full mechanistic PK-PD model for 5-HT1A receptor agonists has been obtained, which is highly predictive of the in vivo intrinsic efficacy and a highly significant correlation was observed between the efficacy parameters in vivo and in vitro. Expand
Pharmacokinetics of sertindole and its metabolite dehydrosertindole in rats and characterization of their comparative pharmacodynamics based on in vivo D2 receptor occupancy and behavioural conditioned avoidance response
TLDR
Based on competitive PK/PD analysis of the parent–metabolite interaction, the relative contribution of dehydrosertindole to the overall pharmacological effect after sertindoles administration in rats appeared to be of minor significance. Expand
Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population pharmacokinetic-pharmacodynamic data.
AIMS To describe the population pharmacokinetic-pharmacodynamic relationship between darifenacin (UK-88,525) and its hydroxylated metabolite (UK-148,993), and the reduction in salivary flow (SF, aExpand
Pharmacokinetic-Pharmacodynamic Modeling of the Antinociceptive Effect of Buprenorphine and Fentanyl in Rats: Role of Receptor Equilibration Kinetics
TLDR
The findings of this study show that the rate-limiting step in the onset and offset of buprenorphine's antinociceptive effect is distribution to the brain. Expand
CYP2D6 CATALYZES 5-HYDROXYLATION OF 1-(2-PYRIMIDINYL)-PIPERAZINE, AN ACTIVE METABOLITE OF SEVERAL PSYCHOACTIVE DRUGS, IN HUMAN LIVER MICROSOMES
TLDR
Results indicate that polymorphic CYP2D6 is responsible for the conversion of 1-PP to HO-1-PP, the major metabolite in the human circulation and in rat brains following oral administration of buspirone. Expand
Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokinetic‐pharmacodynamic modelling approach
TLDR
A thorough characterization of the pharmacokinetic (PK) properties of tesofensine and M1 in mice is accomplished and the potency and concentration‐time course of the active metabolite M1 relative to tes ofensine are evaluated using the PK/PD modelling approach. Expand
Application of a combined effect compartment and binding model for gastric acid inhibition of AR-HO47108: a potassium competitive acid blocker, and its active metabolite AR-HO47116 in the dog.
TLDR
There is a delay between the plasma concentration-time peak and the maximum inhibitory effect and that the effect persisted longer than anticipated from the Plasma concentration half-lives of the compounds and the peak effect was reached earlier at higher doses. Expand
5.38 – Mechanism-Based Pharmacokinetic–Pharmacodynamic Modeling for the Prediction of In Vivo Drug Concentration–Effect Relationships – Application in Drug Candidate Selection and Lead Optimization
TLDR
The objective is the prediction of the PK/PD properties of novel drugs in humans on the basis of information from in vitro bioassays and in vivo animal studies with the aim of improving lead optimization and drug candidate selection. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 55 REFERENCES
1-(2-Pyrimidinyl)-piperazine as active metabolite of buspirone in man and rat.
TLDR
Results, together with the fact that PmP is biochemically and pharmacologically active, suggest that the metabolite may contribute significantly to the central effects of the parent drug. Expand
The alpha 2-adrenoceptor antagonist activity of ipsapirone and gepirone is mediated by their common metabolite 1-(2-pyrimidinyl)-piperazine (PmP).
TLDR
Data indicate that PmP formation is a pharmacologically significant metabolic process for the buspirone-related drugs, ipsapirone and gepirone, and that this metabolite is responsible for the alpha 2-adrenoceptor blocking activity exerted by these drugs in vivo in the rat. Expand
Disposition of the psychotropic drugs buspirone, MJ-13805 and piribedil, and of their common active metabolite 1-(2-pyrimidinyl)-piperazine in the rat.
TLDR
Results indicate that PmP formation is a pharmacologically significant process for both buspirone and MJ-13805 but it is probably less important for piribedil. Expand
Comparative behavioural profiles of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine (1-PP) in the murine elevated plus-maze
TLDR
Data suggest that any anxiolytic activity of buspirone in the murine plus-maze may be attributable to its principal active metabolite, 1-PP, which produced dose-dependent anti-anxiety effects on both conventional and ethological measures that were not confounded by motoric impairment. Expand
Metabolism of the antianxiety drug buspirone in human subjects.
TLDR
The metabolism of an oral dose of the antianxiety drug buspirone labeled with 14C/15N was studied in human subjects to facilitate structural characterization of the metabolites by mass spectrometry. Expand
Metabolism of the antianxiety drug buspirone in the rat.
TLDR
Seven major metabolites of the antianxiety drug buspirone were unambiguously identified together with unchanged drug and accounted for greater than 90% of the total metabolites excreted in the rat bile and urine samples. Expand
Pharmacokinetic-pharmacodynamic modelling of the hypothermic and corticosterone effects of the 5-HT1A receptor agonist flesinoxan.
TLDR
It is shown that customizing the animal prior to the experiment has no influence on the pharmacokinetic-pharmacodynamic parameter estimates, and the similarity in potency between the hypothermic and corticosterone effects suggests that both are mediated via tissues with a similar receptor-effector coupling efficiency. Expand
The azapirone metabolite 1-(2-pyrimidinyl)piperazine depresses excitatory synaptic transmission in the hippocampus of the alert rat via 5-HT1A receptors.
TLDR
The effects of acute and repeated treatment with 1-(2-pyrimidinyl)piperazine (1-PP), a metabolite of the 5-HT1A receptor ligand azapirones, were investigated on hippocampal excitatory synaptic transmission to indicate that the previously reported reduction in the e.p.s.s.'s may be mediated in part by their metabolite 1-PP through activation of 5- HT1A receptors. Expand
Analysis of the hypothermic action of 8-hydroxy-2-(di-N-propylamino)-tetralin, and of 1-(2-pyrimidinyl)-piperazine and its derivatives
The hypothermic activity of 8-OH-DRAT, 1-(2-pyrimidinyl) piperazine (1-PP), buspirone and its structure analogues tightly correlates with the degree of inhibition of 3H-serotonine release byExpand
A competitive interaction model predicts the effect of WAY-100,635 on the time course of R-(+)-8-hydroxy-2-(di-n-propylamino)tetralin-induced hypothermia.
TLDR
The findings of this investigation show that, in contrast to earlier reports in the literature, WAY 100,635 behaves as a pure competitive antagonist at the 5-hydroxytryptamine(1A) receptor in vivo. Expand
...
1
2
3
4
5
...